Latest Peplin news
09-June-09
Peplin Initiates Phase 3 Clinical Trials with PEP005 Gel in AK on Face and Scalp read more
28-May-09
Peplin's Positive Phase II AK Trial Results Published in JAAD read more
17-May-09
Positive Results for Peplin's First Phase III AK Trial read more
15-May-09
Peplin Results for the Quarter Ended 31 March 2009 read more
Scientific Posters
Basic Science
| Authors | Title | Reference |
|---|---|---|
| Ogbourne SM, Parsons P, Suhrbier A | Novel Mechanism of Action Predicts Short Course of Therapy of PEP005 for Topical Applications click here to view poster | Poster presented at the 21stWorld Congress of Dermatology, October 1 to 5, 2007, Buenos Aires, Argentina |
| Ogbourne SM, Parsons P, Challacombe J, Suhrbier A | Mechanism of action of PEP005 for topical applications click here to view poster | Poster presented at the Summer American Academy of Dermatology August 1 to 5, 2007, New York, New York, USA |
Clinical
| Authors | Title | Reference |
|---|---|---|
| Berman B | Discovery and development timeline of a novel treatment for actinic keratosis: PEP005 (ingenol mebutate) Gel click here to view poster | Poster presented at the South Beach Symposium February 13, 2009 in Miami, FL |
| Anderson L, Schmieder GJ, Werschler WP, Tschen EH, Ling MR, Stow DB, Katsamas J | Safety and efficacy of ingenol mebutate (PEP005) gel, 0.025% and 0.05%, for actinic keratosis click here to view poster | Poster presented at Summer Academy 08, American Academy of Dermatology meeting, July 30 to August 03, 08, Chicago, IL, USA |
| Anderson L, Schmieder GJ, Werschler WP, Tschen EH, Ling MR, Stow DB, Welburn, P | Efficacy and tolerability of ingenol mebutate (PEP005) gel, 0.025% and 0.05%, for scalp and non-scalp actinic keratosis click here to view poster | Poster presented at Summer Academy 08, American Academy of Dermatology meeting, July 30 to August03, 08, Chicago, IL, USA |
| Freeman M, Oakley A, Siller G, Rosen R, Salmon P, Spelman L, Shumack S, Rubel D, Birchall N, Katsamas K | Study to determine the optimal tolerated regimen of ingenol mebutate (PEP005) gel for actinic keratosis of the face or face and scalp click here to view poster | Poster presented at Summer Academy 08, American Academy of Dermatology meeting, July 30 to August 03, 08, Chicago, IL, USA |
| Rosen RH, Katsamas J, Ogbourne SM, Welburn P | Early Phase Clinical Development of PEP005 Topical Gel for Basal Cell Carcinoma click here to view poster | Poster presented at the 21st World Congress of Dermatology meeting, October 1 to 5, 2007, Buenos Aires, Argentina |
| Rosen RH, Freeman M, Siller G, Ogbourne SM | Safety and Efficacy of PEP005 Topical Gel for the Treatment of Squamous Cell Carcinoma In Situ click here to view poster | Poster presented at the 21stWorld Congress of Dermatology, October 1–5, 2007, Buenos Aires, Argentina |
| Anderson L, Welburn P | Maximum tolerated dose of PEP005 Topical Gel for the treatment of actinic keratosis click here to view poster | Poster presented at the Summer American Academy of Dermatology August 1 to 5, 2007, New York, New York, USA |
| Rosen RH, Freeman M, Siller G, Katsamas J, Ogbourne SM | Safety and efficacy of PEP005 Topical Gel for the treatment of nodular and superficial forms of basal cell carcinoma click here to view poster | Poster presented at the Summer American Academy of Dermatology August 1 to 5, 2007, New York, New York, USA |
| Welburn P, Dosik JS | Skin sensitization potential of PEP005 Topical Gel click here to view poster | Poster presented at the Summer American Academy of Dermatology August 1 to 5, 2007, New York, New York, USA |
| Anderson L, Katsamas J, Welburn P | Early Phase Clinical Development of PEP005 Topical Gel for Actinic Keratoses click here to view poster | Poster presented at the 21st World Congress of Dermatology, October 1–5, 2007, Buenos Aires, Argentina |